![]() |
½ÃÀ庸°í¼
»óÇ°ÄÚµå
1619138
PD-1 ¹× PD-L1 ¾ïÁ¦Á¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Á¦Ç°º°, ÀûÀÀÁõº°, À¯Åë ä³Îº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2024-2031³â)PD-1 and PD-L1 Inhibitors Market Size, Share, Growth Analysis, By Product (Nivolumab, Pembrolizumab), By Indication (Melanoma, Non-Small Cell Lung Cancer (NSCLC)), By Distribution Channel, By Region - Industry Forecast 2024-2031 |
¼¼°è PD-1 ¹× PD-L1 ¾ïÁ¦Á¦ ½ÃÀå ±Ô¸ð´Â 2022³â 468¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2023³â 551¾ï 8,000¸¸ ´Þ·¯¿¡¼ 2031³â 2,060¾ï ´Þ·¯·Î ¿¹Ãø ±â°£(2024-2031³â) µ¿¾È 17.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
PD-1 ¹× PD-L1 ¾ïÁ¦Á¦ ½ÃÀåÀº ¾Ï ¹ßº´·üÀÇ Áõ°¡¿Í ¸é¿ªÄ¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ±Þ°ÝÇÑ ¼ºÀå¼¼¸¦ º¸ÀÌ°í ÀÖ½À´Ï´Ù. 2014³â FDA°¡ Æèºê·Ñ¸®ÁÖ¸¿(Å°Æ®·ç´Ù)À» ½ÂÀÎÇÑ ÀÌÈÄ ´Ïº¼·ç¸¿, ¾ÆÅ×Á¹¸®ÁÖ¸¿, ¾ÆÅ×Á¹¸®ÁÖ¸¿ µî ´Ù¾çÇÑ ¾ïÁ¦Á¦µéÀÌ ½ÃÀå¿¡ ÁøÀÔÇÏ°í ÀÖ½À´Ï´Ù. ½ÃÀå¿¡ ÁøÀÔÇÏ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â źźÇÑ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ ÇöÀç ½ÃÀåÀ» ¼±µµÇÏ°í ÀÖÁö¸¸, ¸é¿ªÄ¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼ÀÇ ¼ºÀåÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ¸ÓÅ©, ·Î½´, ºê¸®½ºÅ縶À̾½ºÄûºê µî ÁÖ¿ä ±â¾÷µéÀÌ Àû±ØÀûÀ¸·Î °³¹ßÀ» ÁøÇàÇÏ°í ÆÄÆ®³Ê½ÊÀ» ¸Î°í ÀÖ½À´Ï´Ù. ´Ù¸¸, ¸ÂÃãÇü ÀÇ·á ºÐ¾ßÀÇ °æÀïÀÌ Ä¡¿ÇØÁö¸é¼ ³ôÀº Ä¡·á ºñ¿ë°ú ºÎÀÛ¿ëÀÌ ½ÃÀå È®´ë¸¦ ÀúÇØÇÒ °¡´É¼ºµµ ÀÖ½À´Ï´Ù.
Global PD-1 and PD-L1 Inhibitors Market size was valued at USD 46.8 billion in 2022 and is poised to grow from USD 55.18 billion in 2023 to USD 206.0 billion by 2031, growing at a CAGR of 17.9% during the forecast period (2024-2031).
The PD-1/PD-L1 inhibitor market has experienced transformative growth, driven by rising cancer prevalence and heightened awareness of immunotherapy. These innovative drugs target immune evasion mechanisms, successfully enabling T cells to combat various cancers, including lung, melanoma, and bladder cancers. Since the FDA's approval of pembrolizumab (Keytruda) in 2014, numerous inhibitors have entered the market, including nivolumab and atezolizumab. North America currently leads the market due to its robust healthcare infrastructure, but growth is anticipated in the Asia-Pacific region as awareness of immunotherapy rises. Key players like Merck, Roche, and Bristol-Myers Squibb are actively advancing development and forming partnerships. Nevertheless, high treatment costs and side effects could temper market expansion amidst emerging competition in personalized medicine.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pd-1 and Pd-L1 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pd-1 and Pd-L1 Inhibitors Market Segmental Analysis
Global PD-1 and PD-L1 Inhibitors Market is segmented by product, indication, distribution channel and region. Based on product, the market is segmented into nivolumab, pembrolizumab, atezolizumab, avelumab and durvalumab. Based on indication, the market is segmented into melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell cancer (HNSCC), bladder cancer, merkel cell carcinoma (MCC) and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pd-1 and Pd-L1 Inhibitors Market
The global PD-1 and PD-L1 inhibitors market is primarily driven by the escalating prevalence of cancer. With cancer positioned as the second leading cause of death worldwide, the World Health Organization projected approximately 12 million fatalities in 2022 alone. The notable effectiveness of PD-1 and PD-L1 inhibitors in treating diverse cancer types, including lung cancer, melanoma, and bladder cancer, underscores their importance in therapeutic applications. As the incidence of cancer continues to rise and the demand for efficient treatment alternatives grows, the PD-1 and PD-L1 inhibitors market is poised for significant expansion in response to these pressing healthcare needs.
Restraints in the Global Pd-1 and Pd-L1 Inhibitors Market
The global PD-1 and PD-L1 inhibitors market faces significant restraints primarily due to the high costs associated with these therapies. These inhibitors tend to be expensive, thereby restricting access for many patients, especially in developing regions. Moreover, the potential side effects-ranging from fatigue and nausea to diarrhoea-can further deter patients from opting for these advanced treatments. As a result, both healthcare providers and patients might gravitate towards more affordable alternatives like conventional chemotherapy. This situation not only imposes a financial strain on healthcare systems and insurance providers but also affects their willingness to reimburse the costs of these specialized drugs.
Market Trends of the Global Pd-1 and Pd-L1 Inhibitors Market
A significant trend shaping the global PD-1 and PD-L1 inhibitors market is the escalating emphasis on combination therapies. Recent studies indicate that integrating PD-1/PD-L1 inhibitors with other therapeutic modalities, such as chemotherapy or alternative immunotherapies, can markedly enhance treatment efficacy and mitigate the potential for resistance development. Major market players are channeling substantial resources into the formulation and clinical testing of innovative combination regimens, reflecting a collective effort to optimize patient outcomes. This trend is poised to gain momentum in the ensuing years as the medical community endeavors to transcend the constraints associated with PD-1/PD-L1 inhibitors when used as standalone treatments.